Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy
NCT03071133 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 344
Last updated 2022-02-23
Summary
An observational, postmarketing commitment following the marketing authorization for DCV Trio therapy in Japan
Conditions
- Hepatitis C
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-01-01
- Primary Completion
- 2019-01-08
- Completion
- 2019-01-08
Countries
- Japan
Study Locations
More Related Trials
-
Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV
NCT02124044 ·Status: COMPLETED ·Phase: PHASE2
-
Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
NCT01581203 ·Status: COMPLETED ·Phase: PHASE3
-
UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects
NCT01979939 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1
NCT02170727 ·Status: COMPLETED ·Phase: PHASE3
-
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
NCT01492504 ·Status: COMPLETED
-
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
NCT01973049 ·Status: COMPLETED ·Phase: PHASE3
-
Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus
NCT02098616 ·Status: COMPLETED ·Phase: NA
-
Drug Use-Results Survey in Participants Infected With Hepatitis C Virus Genotype 2
NCT02945228 ·Status: COMPLETED
-
Effectiveness, Safety and Clinical Outcomes of Paritaprevir/Ombitasvir/r+Dasabuvir 8 Weeks
NCT03122132 ·Status: COMPLETED
-
Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection
NCT02023099 ·Status: COMPLETED ·Phase: PHASE3
-
To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet
NCT02108639 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection
NCT02023112 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients
NCT01016912 ·Status: COMPLETED ·Phase: PHASE2
-
An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject
NCT01051414 ·Status: COMPLETED ·Phase: PHASE2
-
Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6
NCT03341871 ·Status: COMPLETED
-
Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1
NCT02629172 ·Status: COMPLETED
-
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection
NCT02707952 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection
NCT02496078 ·Status: COMPLETED ·Phase: PHASE3
-
Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen
NCT02309450 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
NCT02441283 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients
NCT01970904 ·Status: COMPLETED ·Phase: NA
-
Study in Healthy Adults to Evaluate Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir
NCT00931281 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016)
NCT00880763 ·Status: COMPLETED ·Phase: PHASE2
-
A First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects
NCT01332552 ·Status: TERMINATED ·Phase: PHASE1
-
Food Effect of a Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325
NCT02095860 ·Status: COMPLETED ·Phase: PHASE1